The discovery of non-basic atrial natriuretic peptide clearance receptor antagonists. Part 1
CA Veale, VC Alford, D Aharony, DL Banville… - Bioorganic & medicinal …, 2000 - Elsevier
CA Veale, VC Alford, D Aharony, DL Banville, RA Bialecki, FJ Brown, JR Damewood Jr…
Bioorganic & medicinal chemistry letters, 2000•ElsevierThe cyclic peptide ANP 4-23 and the linear peptide analogue AP-811 have been shown to
be selective ANP-CR antagonists. Via alanine scanning and truncation studies we sought to
determine which residues in these molecules were important in their binding to the
clearance receptor and the relationship between these two molecules. These studies show
that several modifications to these compounds are possible which improve physical
properties of these molecules while retaining high affinity for the ANP-CR.
be selective ANP-CR antagonists. Via alanine scanning and truncation studies we sought to
determine which residues in these molecules were important in their binding to the
clearance receptor and the relationship between these two molecules. These studies show
that several modifications to these compounds are possible which improve physical
properties of these molecules while retaining high affinity for the ANP-CR.
The cyclic peptide ANP 4-23 and the linear peptide analogue AP-811 have been shown to be selective ANP-CR antagonists. Via alanine scanning and truncation studies we sought to determine which residues in these molecules were important in their binding to the clearance receptor and the relationship between these two molecules. These studies show that several modifications to these compounds are possible which improve physical properties of these molecules while retaining high affinity for the ANP-CR.
Elsevier
